Avanir Pain Drug Successful in Late-Stage Trial
Posted on: Wednesday, 18 April 2007, 15:00 CDT
Avanir Pharmaceuticals has said it diabetic pain drug, Zenvia, alleviated symptoms in a phase III trial.
The drug met the primary endpoint and both Zenvia treatment groups had lower pain ratings than placebo patients.
Zenvia also demonstrated statistically significant improvements in a number of key secondary endpoints including the pain relief ratings scale and the pain intensity ratings scale. The secondary endpoints compared the baseline value to the average rating values at each study visit after randomization.
Overall, the safety data from this study are consistent with data from previous studies. The most commonly reported adverse events were dizziness, nausea, diarrhea, fatigue and somnolence and were generally mild to moderate in nature.
"We are extremely encouraged by the results of this trial which are consistent with Avanir's prior phase II study in patients with diabetic neuropathic pain," said Randall Kaye, senior vice president of Avanir Pharmaceuticals.
Avanir now has two phase III Zenvia programs in areas with significant unmet medical need, one in involuntary emotional expression disorder (IEED) and one in diabetic neuropathic pain.
Source: Datamonitor
Related Articles
- Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
- XTL Completes Patient Randomization in Phase IIb Study of Diabetic Pain Drug
- Array BioPharma's Pain Drug Meets Phase II Study Endpoints
- AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
- Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
- Pain Therapeutics Initiates Phase III Study With Oxytrex(TM)
- FibroGen Reports Results of a Phase 1b Study of FG-3019, Therapeutic Antibody Against CTGF, in Diabetic Patients With Microalbuminuria
- Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, Showed Significantly Reduced Blood Sugar Levels When Used As Monotherapy or As Add-On Treatment
- Speedel Starts Phase III Study of SPP301 in Diabetic Nephropathy
- NicOx Announces NCX 4016 More Effective Than Aspirin at Preventing Platelet Activation in Diabetes in Phase IIa Study
 |
 |
User Comments (0)
RSS Feeds